nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP3A4—Topotecan—ovarian cancer	0.0389	0.272	CbGbCtD
Bexarotene—CYP2C9—Paclitaxel—ovarian cancer	0.0331	0.232	CbGbCtD
Bexarotene—CYP3A4—Vinorelbine—ovarian cancer	0.0274	0.192	CbGbCtD
Bexarotene—CYP3A4—Paclitaxel—ovarian cancer	0.0192	0.135	CbGbCtD
Bexarotene—CYP3A4—Docetaxel—ovarian cancer	0.0139	0.0973	CbGbCtD
Bexarotene—CYP3A4—Doxorubicin—ovarian cancer	0.0104	0.0726	CbGbCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.0014	0.00614	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—ERBB2—ovarian cancer	0.0014	0.00612	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—MAPK1—ovarian cancer	0.00134	0.00587	CbGpPWpGaD
Bexarotene—RXRA—Orphan transporters—TUBB3—ovarian cancer	0.00131	0.00573	CbGpPWpGaD
Bexarotene—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.00128	0.00559	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00126	0.0055	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—RBL2—ovarian cancer	0.00125	0.00546	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—NR5A1—ovarian cancer	0.00119	0.00522	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.00114	0.005	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—ESR1—ovarian cancer	0.00114	0.00498	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—NR5A1—ovarian cancer	0.00112	0.0049	CbGpPWpGaD
Bexarotene—CYP2C9—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.00109	0.00476	CbGpPWpGaD
Bexarotene—RXRG—Vitamin A and Carotenoid Metabolism—MAPK1—ovarian cancer	0.00107	0.00468	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—YAP1—ovarian cancer	0.00104	0.00456	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—ovarian cancer	0.00103	0.00451	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—ovarian cancer	0.00102	0.00446	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.00102	0.00446	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—AKT1—ovarian cancer	0.00101	0.00443	CbGpPWpGaD
Bexarotene—RXRB—Vitamin A and Carotenoid Metabolism—MAPK1—ovarian cancer	0.00101	0.0044	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—CCND1—ovarian cancer	0.001	0.00437	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—MET—ovarian cancer	0.000999	0.00437	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—ovarian cancer	0.000971	0.00424	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—AKT1—ovarian cancer	0.000952	0.00416	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.0009	0.00393	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—PIK3CA—ovarian cancer	0.000896	0.00392	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—CDH1—ovarian cancer	0.000865	0.00378	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—IL6ST—ovarian cancer	0.000855	0.00374	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—PIK3CA—ovarian cancer	0.000843	0.00368	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—HRAS—ovarian cancer	0.000829	0.00363	CbGpPWpGaD
Bexarotene—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	0.000812	0.00355	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—WDR77—ovarian cancer	0.000806	0.00352	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—MYC—ovarian cancer	0.000802	0.00351	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—HRAS—ovarian cancer	0.00078	0.00341	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—WDR77—ovarian cancer	0.000758	0.00331	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—GADD45A—ovarian cancer	0.000744	0.00325	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—MAPK3—ovarian cancer	0.000736	0.00322	CbGpPWpGaD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—AKT1—ovarian cancer	0.000732	0.0032	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—ERBB2—ovarian cancer	0.00073	0.00319	CbGpPWpGaD
Bexarotene—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000717	0.00314	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—ovarian cancer	0.000704	0.00308	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—MAPK1—ovarian cancer	0.0007	0.00306	CbGpPWpGaD
Bexarotene—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.0007	0.00306	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—IL6—ovarian cancer	0.000689	0.00301	CbGpPWpGaD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—AKT1—ovarian cancer	0.000688	0.00301	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—YAP1—ovarian cancer	0.00068	0.00297	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—SLC5A5—ovarian cancer	0.000667	0.00292	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—SLC2A1—ovarian cancer	0.000644	0.00282	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—YAP1—ovarian cancer	0.00064	0.0028	CbGpPWpGaD
Bexarotene—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.00064	0.0028	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—TTF1—ovarian cancer	0.000632	0.00277	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000609	0.00266	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—TTF1—ovarian cancer	0.000595	0.0026	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—PGR—ovarian cancer	0.000594	0.0026	CbGpPWpGaD
Bexarotene—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	0.000589	0.00258	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—NR5A1—ovarian cancer	0.000584	0.00256	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NR5A1—ovarian cancer	0.000574	0.00251	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—ovarian cancer	0.000574	0.00251	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—PGR—ovarian cancer	0.000558	0.00244	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—CTNNB1—ovarian cancer	0.000558	0.00244	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—PARP1—ovarian cancer	0.000552	0.00241	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NR5A1—ovarian cancer	0.00055	0.00241	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000547	0.00239	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000543	0.00238	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP1B1—ovarian cancer	0.000542	0.00237	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NR5A1—ovarian cancer	0.00054	0.00236	CbGpPWpGaD
Bexarotene—RXRA—Vitamin A and Carotenoid Metabolism—MAPK1—ovarian cancer	0.000525	0.00229	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—PARP1—ovarian cancer	0.000519	0.00227	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—ovarian cancer	0.000506	0.00221	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.0005	0.00219	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—AKT1—ovarian cancer	0.000496	0.00217	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—STAT3—ovarian cancer	0.000486	0.00213	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00047	0.00205	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000468	0.00205	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000464	0.00203	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—PIK3CA—ovarian cancer	0.000439	0.00192	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000424	0.00185	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—AQP3—ovarian cancer	0.000422	0.00185	CbGpPWpGaD
Bexarotene—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000422	0.00184	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—IL6ST—ovarian cancer	0.000419	0.00183	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000418	0.00183	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.00041	0.00179	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.00041	0.00179	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—ovarian cancer	0.000406	0.00178	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HNF1B—ovarian cancer	0.000406	0.00177	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ATP7B—ovarian cancer	0.000405	0.00177	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000403	0.00176	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000402	0.00176	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—WDR77—ovarian cancer	0.000395	0.00173	CbGpPWpGaD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000383	0.00168	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000381	0.00166	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—ovarian cancer	0.000359	0.00157	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—IL6—ovarian cancer	0.00034	0.00148	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—YAP1—ovarian cancer	0.000333	0.00146	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NME2—ovarian cancer	0.00033	0.00144	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—YAP1—ovarian cancer	0.000328	0.00143	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—TUBB3—ovarian cancer	0.00032	0.0014	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—ESR1—ovarian cancer	0.000317	0.00139	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000313	0.00137	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—TTF1—ovarian cancer	0.00031	0.00136	CbGpPWpGaD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00031	0.00135	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—YAP1—ovarian cancer	0.000308	0.00135	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000306	0.00134	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—ESR1—ovarian cancer	0.000298	0.0013	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000296	0.00129	CbGpPWpGaD
Bexarotene—Cough—Docetaxel—ovarian cancer	0.000292	0.000464	CcSEcCtD
Bexarotene—Angina pectoris—Doxorubicin—ovarian cancer	0.000292	0.000464	CcSEcCtD
Bexarotene—Insomnia—Paclitaxel—ovarian cancer	0.000291	0.000463	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—PGR—ovarian cancer	0.000291	0.00127	CbGpPWpGaD
Bexarotene—Pneumonia—Epirubicin—ovarian cancer	0.00029	0.000462	CcSEcCtD
Bexarotene—Paraesthesia—Paclitaxel—ovarian cancer	0.000289	0.00046	CcSEcCtD
Bexarotene—Hypertension—Docetaxel—ovarian cancer	0.000289	0.000459	CcSEcCtD
Bexarotene—Bronchitis—Doxorubicin—ovarian cancer	0.000288	0.000458	CcSEcCtD
Bexarotene—Dyspnoea—Paclitaxel—ovarian cancer	0.000287	0.000457	CcSEcCtD
Bexarotene—Somnolence—Paclitaxel—ovarian cancer	0.000286	0.000456	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PGR—ovarian cancer	0.000286	0.00125	CbGpPWpGaD
Bexarotene—Arthralgia—Docetaxel—ovarian cancer	0.000285	0.000453	CcSEcCtD
Bexarotene—Myalgia—Docetaxel—ovarian cancer	0.000285	0.000453	CcSEcCtD
Bexarotene—Chest pain—Docetaxel—ovarian cancer	0.000285	0.000453	CcSEcCtD
Bexarotene—Pancytopenia—Doxorubicin—ovarian cancer	0.000284	0.000453	CcSEcCtD
Bexarotene—Nausea—Vinorelbine—ovarian cancer	0.000284	0.000452	CcSEcCtD
Bexarotene—Dyspepsia—Paclitaxel—ovarian cancer	0.000283	0.000451	CcSEcCtD
Bexarotene—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000283	0.00045	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000283	0.00045	CcSEcCtD
Bexarotene—RXRA—Gene Expression—NR5A1—ovarian cancer	0.000281	0.00123	CbGpPWpGaD
Bexarotene—Jaundice—Epirubicin—ovarian cancer	0.000281	0.000448	CcSEcCtD
Bexarotene—Stomatitis—Epirubicin—ovarian cancer	0.000281	0.000448	CcSEcCtD
Bexarotene—Conjunctivitis—Epirubicin—ovarian cancer	0.000281	0.000446	CcSEcCtD
Bexarotene—Urinary tract infection—Epirubicin—ovarian cancer	0.000281	0.000446	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.00028	0.00123	CbGpPWpGaD
Bexarotene—Dysuria—Doxorubicin—ovarian cancer	0.00028	0.000446	CcSEcCtD
Bexarotene—Neutropenia—Doxorubicin—ovarian cancer	0.00028	0.000446	CcSEcCtD
Bexarotene—Decreased appetite—Paclitaxel—ovarian cancer	0.00028	0.000445	CcSEcCtD
Bexarotene—Dry mouth—Docetaxel—ovarian cancer	0.000278	0.000443	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000278	0.000442	CcSEcCtD
Bexarotene—Fatigue—Paclitaxel—ovarian cancer	0.000278	0.000442	CcSEcCtD
Bexarotene—Sweating—Epirubicin—ovarian cancer	0.000277	0.00044	CcSEcCtD
Bexarotene—Pollakiuria—Doxorubicin—ovarian cancer	0.000277	0.00044	CcSEcCtD
Bexarotene—Constipation—Paclitaxel—ovarian cancer	0.000275	0.000438	CcSEcCtD
Bexarotene—Pain—Paclitaxel—ovarian cancer	0.000275	0.000438	CcSEcCtD
Bexarotene—Haematuria—Epirubicin—ovarian cancer	0.000275	0.000438	CcSEcCtD
Bexarotene—Confusional state—Docetaxel—ovarian cancer	0.000275	0.000438	CcSEcCtD
Bexarotene—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000273	0.000435	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—CTNNB1—ovarian cancer	0.000273	0.0012	CbGpPWpGaD
Bexarotene—Oedema—Docetaxel—ovarian cancer	0.000273	0.000434	CcSEcCtD
Bexarotene—Weight increased—Doxorubicin—ovarian cancer	0.000273	0.000434	CcSEcCtD
Bexarotene—Epistaxis—Epirubicin—ovarian cancer	0.000272	0.000433	CcSEcCtD
Bexarotene—Infection—Docetaxel—ovarian cancer	0.000271	0.000431	CcSEcCtD
Bexarotene—Weight decreased—Doxorubicin—ovarian cancer	0.000271	0.000431	CcSEcCtD
Bexarotene—Sinusitis—Epirubicin—ovarian cancer	0.000271	0.000431	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—PARP1—ovarian cancer	0.000271	0.00118	CbGpPWpGaD
Bexarotene—Hyperglycaemia—Doxorubicin—ovarian cancer	0.00027	0.00043	CcSEcCtD
Bexarotene—RXRB—Gene Expression—PGR—ovarian cancer	0.000269	0.00118	CbGpPWpGaD
Bexarotene—Pneumonia—Doxorubicin—ovarian cancer	0.000269	0.000427	CcSEcCtD
Bexarotene—Shock—Docetaxel—ovarian cancer	0.000268	0.000427	CcSEcCtD
Bexarotene—Nervous system disorder—Docetaxel—ovarian cancer	0.000268	0.000426	CcSEcCtD
Bexarotene—Thrombocytopenia—Docetaxel—ovarian cancer	0.000267	0.000425	CcSEcCtD
Bexarotene—Tachycardia—Docetaxel—ovarian cancer	0.000266	0.000424	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PARP1—ovarian cancer	0.000266	0.00116	CbGpPWpGaD
Bexarotene—Feeling abnormal—Paclitaxel—ovarian cancer	0.000265	0.000422	CcSEcCtD
Bexarotene—Skin disorder—Docetaxel—ovarian cancer	0.000265	0.000422	CcSEcCtD
Bexarotene—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000263	0.000419	CcSEcCtD
Bexarotene—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000262	0.000417	CcSEcCtD
Bexarotene—Haemoglobin—Epirubicin—ovarian cancer	0.00026	0.000414	CcSEcCtD
Bexarotene—Stomatitis—Doxorubicin—ovarian cancer	0.00026	0.000414	CcSEcCtD
Bexarotene—Jaundice—Doxorubicin—ovarian cancer	0.00026	0.000414	CcSEcCtD
Bexarotene—Anorexia—Docetaxel—ovarian cancer	0.00026	0.000414	CcSEcCtD
Bexarotene—Rhinitis—Epirubicin—ovarian cancer	0.00026	0.000413	CcSEcCtD
Bexarotene—Urinary tract infection—Doxorubicin—ovarian cancer	0.00026	0.000413	CcSEcCtD
Bexarotene—Conjunctivitis—Doxorubicin—ovarian cancer	0.00026	0.000413	CcSEcCtD
Bexarotene—Haemorrhage—Epirubicin—ovarian cancer	0.000259	0.000412	CcSEcCtD
Bexarotene—Hypoaesthesia—Epirubicin—ovarian cancer	0.000258	0.00041	CcSEcCtD
Bexarotene—Pharyngitis—Epirubicin—ovarian cancer	0.000257	0.000409	CcSEcCtD
Bexarotene—Sweating—Doxorubicin—ovarian cancer	0.000256	0.000407	CcSEcCtD
Bexarotene—Urinary tract disorder—Epirubicin—ovarian cancer	0.000256	0.000407	CcSEcCtD
Bexarotene—Oedema peripheral—Epirubicin—ovarian cancer	0.000255	0.000406	CcSEcCtD
Bexarotene—Haematuria—Doxorubicin—ovarian cancer	0.000255	0.000405	CcSEcCtD
Bexarotene—Connective tissue disorder—Epirubicin—ovarian cancer	0.000255	0.000405	CcSEcCtD
Bexarotene—Abdominal pain—Paclitaxel—ovarian cancer	0.000255	0.000405	CcSEcCtD
Bexarotene—Body temperature increased—Paclitaxel—ovarian cancer	0.000255	0.000405	CcSEcCtD
Bexarotene—Urethral disorder—Epirubicin—ovarian cancer	0.000254	0.000404	CcSEcCtD
Bexarotene—Epistaxis—Doxorubicin—ovarian cancer	0.000252	0.000401	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000251	0.0011	CbGpPWpGaD
Bexarotene—Sinusitis—Doxorubicin—ovarian cancer	0.000251	0.000399	CcSEcCtD
Bexarotene—RXRB—Gene Expression—PARP1—ovarian cancer	0.00025	0.00109	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000249	0.000396	CcSEcCtD
Bexarotene—Insomnia—Docetaxel—ovarian cancer	0.000247	0.000393	CcSEcCtD
Bexarotene—Paraesthesia—Docetaxel—ovarian cancer	0.000245	0.00039	CcSEcCtD
Bexarotene—Dyspnoea—Docetaxel—ovarian cancer	0.000243	0.000387	CcSEcCtD
Bexarotene—Somnolence—Docetaxel—ovarian cancer	0.000243	0.000386	CcSEcCtD
Bexarotene—Eye disorder—Epirubicin—ovarian cancer	0.000242	0.000385	CcSEcCtD
Bexarotene—Tinnitus—Epirubicin—ovarian cancer	0.000242	0.000384	CcSEcCtD
Bexarotene—Haemoglobin—Doxorubicin—ovarian cancer	0.000241	0.000383	CcSEcCtD
Bexarotene—Cardiac disorder—Epirubicin—ovarian cancer	0.00024	0.000383	CcSEcCtD
Bexarotene—Rhinitis—Doxorubicin—ovarian cancer	0.00024	0.000382	CcSEcCtD
Bexarotene—Dyspepsia—Docetaxel—ovarian cancer	0.00024	0.000382	CcSEcCtD
Bexarotene—Haemorrhage—Doxorubicin—ovarian cancer	0.00024	0.000382	CcSEcCtD
Bexarotene—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000239	0.00038	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—STAT3—ovarian cancer	0.000238	0.00104	CbGpPWpGaD
Bexarotene—Pharyngitis—Doxorubicin—ovarian cancer	0.000238	0.000379	CcSEcCtD
Bexarotene—Decreased appetite—Docetaxel—ovarian cancer	0.000237	0.000378	CcSEcCtD
Bexarotene—Hypersensitivity—Paclitaxel—ovarian cancer	0.000237	0.000378	CcSEcCtD
Bexarotene—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000237	0.000377	CcSEcCtD
Bexarotene—Oedema peripheral—Doxorubicin—ovarian cancer	0.000236	0.000376	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000236	0.000375	CcSEcCtD
Bexarotene—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000236	0.000375	CcSEcCtD
Bexarotene—Fatigue—Docetaxel—ovarian cancer	0.000235	0.000374	CcSEcCtD
Bexarotene—Angiopathy—Epirubicin—ovarian cancer	0.000235	0.000374	CcSEcCtD
Bexarotene—Urethral disorder—Doxorubicin—ovarian cancer	0.000235	0.000374	CcSEcCtD
Bexarotene—Constipation—Docetaxel—ovarian cancer	0.000233	0.000371	CcSEcCtD
Bexarotene—Pain—Docetaxel—ovarian cancer	0.000233	0.000371	CcSEcCtD
Bexarotene—Chills—Epirubicin—ovarian cancer	0.000232	0.00037	CcSEcCtD
Bexarotene—Arrhythmia—Epirubicin—ovarian cancer	0.000231	0.000368	CcSEcCtD
Bexarotene—Asthenia—Paclitaxel—ovarian cancer	0.000231	0.000368	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.00023	0.001	CbGpPWpGaD
Bexarotene—Alopecia—Epirubicin—ovarian cancer	0.000229	0.000364	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000228	0.000999	CbGpPWpGaD
Bexarotene—Pruritus—Paclitaxel—ovarian cancer	0.000228	0.000363	CcSEcCtD
Bexarotene—Malnutrition—Epirubicin—ovarian cancer	0.000226	0.000359	CcSEcCtD
Bexarotene—Erythema—Epirubicin—ovarian cancer	0.000226	0.000359	CcSEcCtD
Bexarotene—Feeling abnormal—Docetaxel—ovarian cancer	0.000225	0.000358	CcSEcCtD
Bexarotene—Eye disorder—Doxorubicin—ovarian cancer	0.000224	0.000357	CcSEcCtD
Bexarotene—Tinnitus—Doxorubicin—ovarian cancer	0.000224	0.000356	CcSEcCtD
Bexarotene—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000223	0.000355	CcSEcCtD
Bexarotene—Cardiac disorder—Doxorubicin—ovarian cancer	0.000222	0.000354	CcSEcCtD
Bexarotene—Flatulence—Epirubicin—ovarian cancer	0.000222	0.000354	CcSEcCtD
Bexarotene—Tension—Epirubicin—ovarian cancer	0.000221	0.000352	CcSEcCtD
Bexarotene—Dysgeusia—Epirubicin—ovarian cancer	0.000221	0.000351	CcSEcCtD
Bexarotene—Diarrhoea—Paclitaxel—ovarian cancer	0.00022	0.000351	CcSEcCtD
Bexarotene—Nervousness—Epirubicin—ovarian cancer	0.000219	0.000349	CcSEcCtD
Bexarotene—Back pain—Epirubicin—ovarian cancer	0.000218	0.000347	CcSEcCtD
Bexarotene—Angiopathy—Doxorubicin—ovarian cancer	0.000218	0.000346	CcSEcCtD
Bexarotene—Muscle spasms—Epirubicin—ovarian cancer	0.000217	0.000345	CcSEcCtD
Bexarotene—Body temperature increased—Docetaxel—ovarian cancer	0.000216	0.000343	CcSEcCtD
Bexarotene—Abdominal pain—Docetaxel—ovarian cancer	0.000216	0.000343	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PPP2R1A—ovarian cancer	0.000216	0.000943	CbGpPWpGaD
Bexarotene—Chills—Doxorubicin—ovarian cancer	0.000215	0.000342	CcSEcCtD
Bexarotene—Arrhythmia—Doxorubicin—ovarian cancer	0.000214	0.000341	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	0.000214	0.000934	CbGpPWpGaD
Bexarotene—Dizziness—Paclitaxel—ovarian cancer	0.000213	0.000339	CcSEcCtD
Bexarotene—RXRA—Metabolism—CYTB—ovarian cancer	0.000213	0.000931	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000213	0.00093	CbGpPWpGaD
Bexarotene—Alopecia—Doxorubicin—ovarian cancer	0.000212	0.000337	CcSEcCtD
Bexarotene—Ill-defined disorder—Epirubicin—ovarian cancer	0.000209	0.000333	CcSEcCtD
Bexarotene—Erythema—Doxorubicin—ovarian cancer	0.000209	0.000332	CcSEcCtD
Bexarotene—Malnutrition—Doxorubicin—ovarian cancer	0.000209	0.000332	CcSEcCtD
Bexarotene—Anaemia—Epirubicin—ovarian cancer	0.000208	0.000332	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000208	0.000911	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000208	0.00091	CbGpPWpGaD
Bexarotene—Agitation—Epirubicin—ovarian cancer	0.000207	0.00033	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	0.000206	0.000902	CbGpPWpGaD
Bexarotene—Flatulence—Doxorubicin—ovarian cancer	0.000206	0.000327	CcSEcCtD
Bexarotene—Tension—Doxorubicin—ovarian cancer	0.000205	0.000326	CcSEcCtD
Bexarotene—Vomiting—Paclitaxel—ovarian cancer	0.000205	0.000326	CcSEcCtD
Bexarotene—Dysgeusia—Doxorubicin—ovarian cancer	0.000204	0.000325	CcSEcCtD
Bexarotene—Malaise—Epirubicin—ovarian cancer	0.000203	0.000324	CcSEcCtD
Bexarotene—Rash—Paclitaxel—ovarian cancer	0.000203	0.000323	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000203	0.000887	CbGpPWpGaD
Bexarotene—Dermatitis—Paclitaxel—ovarian cancer	0.000203	0.000323	CcSEcCtD
Bexarotene—RXRB—Gene Expression—PPP2R1A—ovarian cancer	0.000203	0.000887	CbGpPWpGaD
Bexarotene—Nervousness—Doxorubicin—ovarian cancer	0.000203	0.000323	CcSEcCtD
Bexarotene—Vertigo—Epirubicin—ovarian cancer	0.000203	0.000322	CcSEcCtD
Bexarotene—Syncope—Epirubicin—ovarian cancer	0.000202	0.000322	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	0.000202	0.000884	CbGpPWpGaD
Bexarotene—Leukopenia—Epirubicin—ovarian cancer	0.000202	0.000321	CcSEcCtD
Bexarotene—Back pain—Doxorubicin—ovarian cancer	0.000202	0.000321	CcSEcCtD
Bexarotene—Headache—Paclitaxel—ovarian cancer	0.000202	0.000321	CcSEcCtD
Bexarotene—Hypersensitivity—Docetaxel—ovarian cancer	0.000201	0.00032	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000201	0.000878	CbGpPWpGaD
Bexarotene—Muscle spasms—Doxorubicin—ovarian cancer	0.000201	0.000319	CcSEcCtD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000199	0.000872	CbGpPWpGaD
Bexarotene—Palpitations—Epirubicin—ovarian cancer	0.000199	0.000317	CcSEcCtD
Bexarotene—Loss of consciousness—Epirubicin—ovarian cancer	0.000198	0.000315	CcSEcCtD
Bexarotene—Cough—Epirubicin—ovarian cancer	0.000197	0.000313	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000196	0.000856	CbGpPWpGaD
Bexarotene—Asthenia—Docetaxel—ovarian cancer	0.000196	0.000312	CcSEcCtD
Bexarotene—Hypertension—Epirubicin—ovarian cancer	0.000195	0.00031	CcSEcCtD
Bexarotene—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000194	0.000308	CcSEcCtD
Bexarotene—Pruritus—Docetaxel—ovarian cancer	0.000193	0.000307	CcSEcCtD
Bexarotene—Anaemia—Doxorubicin—ovarian cancer	0.000193	0.000307	CcSEcCtD
Bexarotene—Myalgia—Epirubicin—ovarian cancer	0.000192	0.000306	CcSEcCtD
Bexarotene—Chest pain—Epirubicin—ovarian cancer	0.000192	0.000306	CcSEcCtD
Bexarotene—Arthralgia—Epirubicin—ovarian cancer	0.000192	0.000306	CcSEcCtD
Bexarotene—Agitation—Doxorubicin—ovarian cancer	0.000192	0.000305	CcSEcCtD
Bexarotene—Anxiety—Epirubicin—ovarian cancer	0.000191	0.000305	CcSEcCtD
Bexarotene—Nausea—Paclitaxel—ovarian cancer	0.000191	0.000304	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000191	0.000303	CcSEcCtD
Bexarotene—Discomfort—Epirubicin—ovarian cancer	0.00019	0.000302	CcSEcCtD
Bexarotene—Malaise—Doxorubicin—ovarian cancer	0.000188	0.000299	CcSEcCtD
Bexarotene—Dry mouth—Epirubicin—ovarian cancer	0.000188	0.000299	CcSEcCtD
Bexarotene—Vertigo—Doxorubicin—ovarian cancer	0.000187	0.000298	CcSEcCtD
Bexarotene—Syncope—Doxorubicin—ovarian cancer	0.000187	0.000298	CcSEcCtD
Bexarotene—Leukopenia—Doxorubicin—ovarian cancer	0.000187	0.000297	CcSEcCtD
Bexarotene—Diarrhoea—Docetaxel—ovarian cancer	0.000187	0.000297	CcSEcCtD
Bexarotene—RXRA—Metabolism—PPP1CC—ovarian cancer	0.000186	0.000813	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—BRIP1—ovarian cancer	0.000186	0.000813	CbGpPWpGaD
Bexarotene—Confusional state—Epirubicin—ovarian cancer	0.000186	0.000295	CcSEcCtD
Bexarotene—Palpitations—Doxorubicin—ovarian cancer	0.000184	0.000293	CcSEcCtD
Bexarotene—Oedema—Epirubicin—ovarian cancer	0.000184	0.000293	CcSEcCtD
Bexarotene—Loss of consciousness—Doxorubicin—ovarian cancer	0.000183	0.000292	CcSEcCtD
Bexarotene—Infection—Epirubicin—ovarian cancer	0.000183	0.000291	CcSEcCtD
Bexarotene—Cough—Doxorubicin—ovarian cancer	0.000182	0.00029	CcSEcCtD
Bexarotene—Shock—Epirubicin—ovarian cancer	0.000181	0.000288	CcSEcCtD
Bexarotene—Nervous system disorder—Epirubicin—ovarian cancer	0.000181	0.000287	CcSEcCtD
Bexarotene—Dizziness—Docetaxel—ovarian cancer	0.00018	0.000287	CcSEcCtD
Bexarotene—Thrombocytopenia—Epirubicin—ovarian cancer	0.00018	0.000287	CcSEcCtD
Bexarotene—Hypertension—Doxorubicin—ovarian cancer	0.00018	0.000287	CcSEcCtD
Bexarotene—Tachycardia—Epirubicin—ovarian cancer	0.00018	0.000286	CcSEcCtD
Bexarotene—Skin disorder—Epirubicin—ovarian cancer	0.000179	0.000285	CcSEcCtD
Bexarotene—Hyperhidrosis—Epirubicin—ovarian cancer	0.000178	0.000283	CcSEcCtD
Bexarotene—Myalgia—Doxorubicin—ovarian cancer	0.000178	0.000283	CcSEcCtD
Bexarotene—Arthralgia—Doxorubicin—ovarian cancer	0.000178	0.000283	CcSEcCtD
Bexarotene—Chest pain—Doxorubicin—ovarian cancer	0.000178	0.000283	CcSEcCtD
Bexarotene—Anxiety—Doxorubicin—ovarian cancer	0.000177	0.000282	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.000177	0.000773	CbGpPWpGaD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000176	0.000281	CcSEcCtD
Bexarotene—Discomfort—Doxorubicin—ovarian cancer	0.000176	0.000279	CcSEcCtD
Bexarotene—Anorexia—Epirubicin—ovarian cancer	0.000175	0.000279	CcSEcCtD
Bexarotene—Dry mouth—Doxorubicin—ovarian cancer	0.000174	0.000277	CcSEcCtD
Bexarotene—Vomiting—Docetaxel—ovarian cancer	0.000174	0.000276	CcSEcCtD
Bexarotene—Rash—Docetaxel—ovarian cancer	0.000172	0.000274	CcSEcCtD
Bexarotene—Dermatitis—Docetaxel—ovarian cancer	0.000172	0.000274	CcSEcCtD
Bexarotene—Confusional state—Doxorubicin—ovarian cancer	0.000172	0.000273	CcSEcCtD
Bexarotene—Headache—Docetaxel—ovarian cancer	0.000171	0.000272	CcSEcCtD
Bexarotene—Oedema—Doxorubicin—ovarian cancer	0.00017	0.000271	CcSEcCtD
Bexarotene—Infection—Doxorubicin—ovarian cancer	0.000169	0.000269	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000168	0.000267	CcSEcCtD
Bexarotene—Shock—Doxorubicin—ovarian cancer	0.000168	0.000267	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000167	0.000732	CbGpPWpGaD
Bexarotene—Nervous system disorder—Doxorubicin—ovarian cancer	0.000167	0.000266	CcSEcCtD
Bexarotene—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000167	0.000265	CcSEcCtD
Bexarotene—Insomnia—Epirubicin—ovarian cancer	0.000166	0.000265	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—IL6—ovarian cancer	0.000166	0.000728	CbGpPWpGaD
Bexarotene—Tachycardia—Doxorubicin—ovarian cancer	0.000166	0.000265	CcSEcCtD
Bexarotene—Skin disorder—Doxorubicin—ovarian cancer	0.000165	0.000263	CcSEcCtD
Bexarotene—Paraesthesia—Epirubicin—ovarian cancer	0.000165	0.000263	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—MYC—ovarian cancer	0.000165	0.000721	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000165	0.000262	CcSEcCtD
Bexarotene—Dyspnoea—Epirubicin—ovarian cancer	0.000164	0.000261	CcSEcCtD
Bexarotene—Somnolence—Epirubicin—ovarian cancer	0.000164	0.00026	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000163	0.000712	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000163	0.000712	CbGpPWpGaD
Bexarotene—Anorexia—Doxorubicin—ovarian cancer	0.000162	0.000258	CcSEcCtD
Bexarotene—Nausea—Docetaxel—ovarian cancer	0.000162	0.000258	CcSEcCtD
Bexarotene—Dyspepsia—Epirubicin—ovarian cancer	0.000162	0.000258	CcSEcCtD
Bexarotene—RXRA—Gene Expression—YAP1—ovarian cancer	0.00016	0.000702	CbGpPWpGaD
Bexarotene—Decreased appetite—Epirubicin—ovarian cancer	0.00016	0.000255	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.000159	0.000696	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.000159	0.000696	CbGpPWpGaD
Bexarotene—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000159	0.000253	CcSEcCtD
Bexarotene—Fatigue—Epirubicin—ovarian cancer	0.000159	0.000253	CcSEcCtD
Bexarotene—Pain—Epirubicin—ovarian cancer	0.000157	0.000251	CcSEcCtD
Bexarotene—Constipation—Epirubicin—ovarian cancer	0.000157	0.000251	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000156	0.000682	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—ESR1—ovarian cancer	0.000155	0.00068	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000155	0.000247	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—MYC—ovarian cancer	0.000155	0.000678	CbGpPWpGaD
Bexarotene—Insomnia—Doxorubicin—ovarian cancer	0.000154	0.000245	CcSEcCtD
Bexarotene—Paraesthesia—Doxorubicin—ovarian cancer	0.000153	0.000243	CcSEcCtD
Bexarotene—RXRG—Gene Expression—ESR1—ovarian cancer	0.000153	0.000668	CbGpPWpGaD
Bexarotene—Dyspnoea—Doxorubicin—ovarian cancer	0.000152	0.000242	CcSEcCtD
Bexarotene—Feeling abnormal—Epirubicin—ovarian cancer	0.000152	0.000241	CcSEcCtD
Bexarotene—Somnolence—Doxorubicin—ovarian cancer	0.000151	0.000241	CcSEcCtD
Bexarotene—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000151	0.00024	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.00015	0.000657	CbGpPWpGaD
Bexarotene—Dyspepsia—Doxorubicin—ovarian cancer	0.00015	0.000239	CcSEcCtD
Bexarotene—Decreased appetite—Doxorubicin—ovarian cancer	0.000148	0.000236	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000147	0.000234	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—MET—ovarian cancer	0.000147	0.000642	CbGpPWpGaD
Bexarotene—Fatigue—Doxorubicin—ovarian cancer	0.000147	0.000234	CcSEcCtD
Bexarotene—Pain—Doxorubicin—ovarian cancer	0.000146	0.000232	CcSEcCtD
Bexarotene—Constipation—Doxorubicin—ovarian cancer	0.000146	0.000232	CcSEcCtD
Bexarotene—Abdominal pain—Epirubicin—ovarian cancer	0.000146	0.000232	CcSEcCtD
Bexarotene—Body temperature increased—Epirubicin—ovarian cancer	0.000146	0.000232	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—IL6ST—ovarian cancer	0.000144	0.000629	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—ESR1—ovarian cancer	0.000144	0.000628	CbGpPWpGaD
Bexarotene—Feeling abnormal—Doxorubicin—ovarian cancer	0.00014	0.000223	CcSEcCtD
Bexarotene—RXRA—Gene Expression—PGR—ovarian cancer	0.00014	0.000613	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000139	0.000222	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	0.000138	0.000604	CbGpPWpGaD
Bexarotene—Hypersensitivity—Epirubicin—ovarian cancer	0.000136	0.000216	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	0.000136	0.000593	CbGpPWpGaD
Bexarotene—Body temperature increased—Doxorubicin—ovarian cancer	0.000135	0.000214	CcSEcCtD
Bexarotene—Abdominal pain—Doxorubicin—ovarian cancer	0.000135	0.000214	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	0.000134	0.000584	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	0.000133	0.000583	CbGpPWpGaD
Bexarotene—Asthenia—Epirubicin—ovarian cancer	0.000132	0.00021	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000132	0.000575	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PARP1—ovarian cancer	0.00013	0.00057	CbGpPWpGaD
Bexarotene—Pruritus—Epirubicin—ovarian cancer	0.00013	0.000207	CcSEcCtD
Bexarotene—Diarrhoea—Epirubicin—ovarian cancer	0.000126	0.0002	CcSEcCtD
Bexarotene—Hypersensitivity—Doxorubicin—ovarian cancer	0.000125	0.0002	CcSEcCtD
Bexarotene—RXRA—Metabolism—YAP1—ovarian cancer	0.000125	0.000546	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	0.000123	0.00054	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—NME2—ovarian cancer	0.000123	0.000539	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MMP2—ovarian cancer	0.000123	0.000536	CbGpPWpGaD
Bexarotene—Asthenia—Doxorubicin—ovarian cancer	0.000122	0.000194	CcSEcCtD
Bexarotene—Dizziness—Epirubicin—ovarian cancer	0.000122	0.000194	CcSEcCtD
Bexarotene—Pruritus—Doxorubicin—ovarian cancer	0.000121	0.000192	CcSEcCtD
Bexarotene—Vomiting—Epirubicin—ovarian cancer	0.000117	0.000186	CcSEcCtD
Bexarotene—Diarrhoea—Doxorubicin—ovarian cancer	0.000117	0.000185	CcSEcCtD
Bexarotene—Rash—Epirubicin—ovarian cancer	0.000116	0.000185	CcSEcCtD
Bexarotene—Dermatitis—Epirubicin—ovarian cancer	0.000116	0.000185	CcSEcCtD
Bexarotene—Headache—Epirubicin—ovarian cancer	0.000115	0.000184	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	0.000113	0.000493	CbGpPWpGaD
Bexarotene—Dizziness—Doxorubicin—ovarian cancer	0.000113	0.000179	CcSEcCtD
Bexarotene—Nausea—Epirubicin—ovarian cancer	0.000109	0.000174	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	0.000109	0.000475	CbGpPWpGaD
Bexarotene—Vomiting—Doxorubicin—ovarian cancer	0.000108	0.000172	CcSEcCtD
Bexarotene—Rash—Doxorubicin—ovarian cancer	0.000107	0.000171	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—ERBB2—ovarian cancer	0.000107	0.000469	CbGpPWpGaD
Bexarotene—Dermatitis—Doxorubicin—ovarian cancer	0.000107	0.000171	CcSEcCtD
Bexarotene—Headache—Doxorubicin—ovarian cancer	0.000107	0.00017	CcSEcCtD
Bexarotene—RXRA—Gene Expression—PPP2R1A—ovarian cancer	0.000106	0.000462	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000105	0.000457	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—FASN—ovarian cancer	0.000102	0.000445	CbGpPWpGaD
Bexarotene—Nausea—Doxorubicin—ovarian cancer	0.000101	0.000161	CcSEcCtD
Bexarotene—RXRA—Metabolism—SLC5A5—ovarian cancer	0.0001	0.000438	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—SLC2A1—ovarian cancer	9.66e-05	0.000423	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	9.46e-05	0.000414	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CTNNB1—ovarian cancer	9.39e-05	0.000411	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP1B1—ovarian cancer	9.26e-05	0.000405	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MMP9—ovarian cancer	9.21e-05	0.000403	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	8.53e-05	0.000373	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—VEGFA—ovarian cancer	8.27e-05	0.000362	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PPP2R1A—ovarian cancer	8.22e-05	0.000359	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—STAT3—ovarian cancer	8.19e-05	0.000358	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.18e-05	0.000358	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NRAS—ovarian cancer	8.17e-05	0.000357	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MAPK3—ovarian cancer	8.17e-05	0.000357	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—NME2—ovarian cancer	8.13e-05	0.000356	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—MYC—ovarian cancer	8.08e-05	0.000353	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYTB—ovarian cancer	7.95e-05	0.000347	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MYC—ovarian cancer	7.94e-05	0.000347	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MAPK3—ovarian cancer	7.82e-05	0.000342	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	7.77e-05	0.00034	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MAPK3—ovarian cancer	7.68e-05	0.000336	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ABCB1—ovarian cancer	7.63e-05	0.000334	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TYMS—ovarian cancer	7.49e-05	0.000328	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—ESR1—ovarian cancer	7.48e-05	0.000327	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MYC—ovarian cancer	7.47e-05	0.000327	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—MAPK1—ovarian cancer	7.44e-05	0.000325	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—ovarian cancer	7.44e-05	0.000325	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—KRAS—ovarian cancer	7.03e-05	0.000307	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PPP1CC—ovarian cancer	6.95e-05	0.000304	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—BRIP1—ovarian cancer	6.95e-05	0.000304	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CAV1—ovarian cancer	6.04e-05	0.000264	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—HRAS—ovarian cancer	5.98e-05	0.000261	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.77e-05	0.000252	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—IL6—ovarian cancer	5.72e-05	0.00025	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—AKT1—ovarian cancer	5.51e-05	0.000241	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CG—ovarian cancer	5.5e-05	0.00024	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—AKT1—ovarian cancer	5.28e-05	0.000231	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYTB—ovarian cancer	5.24e-05	0.000229	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—AKT1—ovarian cancer	5.18e-05	0.000226	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	5.06e-05	0.000221	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CD—ovarian cancer	4.83e-05	0.000211	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—YAP1—ovarian cancer	4.66e-05	0.000204	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.61e-05	0.000202	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PPP1CC—ovarian cancer	4.58e-05	0.0002	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—BRIP1—ovarian cancer	4.58e-05	0.0002	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CB—ovarian cancer	4.21e-05	0.000184	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	4.05e-05	0.000177	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MAPK3—ovarian cancer	4e-05	0.000175	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MYC—ovarian cancer	3.89e-05	0.00017	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—FASN—ovarian cancer	3.8e-05	0.000166	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC5A5—ovarian cancer	3.74e-05	0.000163	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PTEN—ovarian cancer	3.64e-05	0.000159	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—SLC2A1—ovarian cancer	3.61e-05	0.000158	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.53e-05	0.000154	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP1B1—ovarian cancer	3.46e-05	0.000151	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—YAP1—ovarian cancer	3.07e-05	0.000134	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	3.07e-05	0.000134	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	3.05e-05	0.000133	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ABCB1—ovarian cancer	2.85e-05	0.000125	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TYMS—ovarian cancer	2.8e-05	0.000122	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—AKT1—ovarian cancer	2.7e-05	0.000118	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PIK3CA—ovarian cancer	2.57e-05	0.000112	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—FASN—ovarian cancer	2.5e-05	0.00011	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.46e-05	0.000108	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.38e-05	0.000104	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.28e-05	9.97e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CAV1—ovarian cancer	2.25e-05	9.86e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.15e-05	9.42e-05	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—AKT1—ovarian cancer	2.1e-05	9.18e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CG—ovarian cancer	2.05e-05	8.98e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.02e-05	8.85e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.88e-05	8.21e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TYMS—ovarian cancer	1.84e-05	8.07e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.8e-05	7.89e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.57e-05	6.88e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CAV1—ovarian cancer	1.49e-05	6.5e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PTEN—ovarian cancer	1.36e-05	5.94e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.35e-05	5.92e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.19e-05	5.21e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.04e-05	4.54e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PIK3CA—ovarian cancer	9.59e-06	4.19e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PTEN—ovarian cancer	8.97e-06	3.92e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—AKT1—ovarian cancer	7.83e-06	3.43e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PIK3CA—ovarian cancer	6.33e-06	2.77e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—AKT1—ovarian cancer	5.17e-06	2.26e-05	CbGpPWpGaD
